HPV Vaccines: state of the art and novel approaches

High-risk genotypes of Human Papillomavirus (HPV) are responsible for cervical cancer and have been shown to be related to the occurrence of other less frequent malignancies (vulva, penis, anus, head and neck). Although in the majority of cases the infection resolves spontaneously, some people fail to clear the virus with an increased risk of neoplastic development. In Italy, HPV vaccination is recommended and offered free of charge to girls and boys from 11 years of age. It is also recommended for immunocompromised patients, individuals with high risk sexual behavior, and women with cervical lesions. The efficacy of HPV vaccination in preventing cervical cancer, especially in uninfected women, has been widely demonstrated. Further advances in technology to improve the efficacy of existing vaccines and the development of novel vaccines are necessary to prevent HPV-associated cancers. The aim of this non-systematic review is to provide an update on the available vaccines and future perspectives for HPV vaccination

Authors

Institutions

Publication Details

Journal
Rivista di immunologia ed allergologia pediatrica.
Published
2024-10-01
DOI
https://doi.org/10.53151/2531-3916/2024-532
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

HPV Vaccines: state of the art and novel approaches

Elisabetta Del Duca, Baldassarre Martire, Veronica Santilli, Mayla Sgrulletti et al.
Rivista di immunologia ed allergologia pediatrica.
Cervical Cancer and HPV Research
article

HPV Vaccines: state of the art and novel approaches

Elisabetta Del Duca, Baldassarre Martire, Veronica Santilli, Mayla Sgrulletti, Giorgio Costagliola, Caterina Rizzo, Viviana Moschese, Giusella Maria Francesca Moscato, Giorgio Ottaviano, Davide Montin, Alessandra Beni, Maria Felicia Mastrototaro
article en

Abstract

High-risk genotypes of Human Papillomavirus (HPV) are responsible for cervical cancer and have been shown to be related to the occurrence of other less frequent malignancies (vulva, penis, anus, head and neck). Although in the majority of cases the infection resolves spontaneously, some people fail to clear the virus with an increased risk of neoplastic development. In Italy, HPV vaccination is recommended and offered free of charge to girls and boys from 11 years of age. It is also recommended for immunocompromised patients, individuals with high risk sexual behavior, and women with cervical lesions. The efficacy of HPV vaccination in preventing cervical cancer, especially in uninfected women, has been widely demonstrated. Further advances in technology to improve the efficacy of existing vaccines and the development of novel vaccines are necessary to prevent HPV-associated cancers. The aim of this non-systematic review is to provide an update on the available vaccines and future perspectives for HPV vaccination

Rivista di immunologia ed allergologia pediatrica.Vol. 38(3)
University of Pisa (IT), University of Rome Tor Vergata (IT), Ospedale di Rivoli (IT), Azienda Ospedaliera San Gerardo (IT), Bambino Gesù Children's Hospital (IT), Ospedale Regina Margherita (IT), Policlinico Tor Vergata (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Azienda Ospedaliera Universitaria Pisana (IT), University of Turin (IT)
Zero hunger
Openalex Percentile: Top 63%
Cervical Cancer and HPV Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.